Combination vaccines decrease the number of injections and improve parental satisfaction and vaccination schedule compliance. In a phase 1, randomized, partially-blinded, single-dose booster study, we evaluated two formulations of an investigational liquid hexavalent vaccine containing diphtheria, tetanus, acellular pertussis (5-component), inactivated poliovirus, Haemophilus influenzae b conjugate and hepatitis B surface antigen (DTaP-IPV-Hib-HBV) in 60 healthy toddlers, 15 to 18 months of age, who had been primed with three doses of a licensed pentavalent diphtheria, tetanus, acellular pertussis (5-component), inactivated poliovirus, Haemophilus influenzae b conjugate (DTaP-IPV//PRP-T) vaccine. The DTaP-IPV//PRP-T vaccine was used as a control in 30 subjects. The investigational formulations, which contained the same DTaP-IPV components, differed only in Hib (content and conjugate) and HBV (content) (PRP-T/HBV10 = 12 mug Hib tetanus toxoid conjugate with 10 microg HBsAg; PRP-OMPC/HBV15 = 6 microg Hib Neisseria meningitidis outer membrane protein complex with 15 microg HBsAg). Injection-site pain, redness and swelling were reported by 46.7%, 46.7%, and 20.0% of the licensed vaccine recipients, 43.3%, 43.3%, and 26.7% of PRP-T/HBV10 recipients and 70.0%, 46.7%, and 46.7% of PRP-OMPC/HBV15 recipients, respectively. Fever > or = 37.8 degrees C and irritability were reported by 0% and 16.7% of licensed vaccine recipients, 10.3% and 23.3% of PRP-T/HBV10 recipients and 30.0% and 16.7% of PRP-OMPC/HBV15 recipients, respectively. There were no apparent differences between the groups in the proportion of participants achieving predefined, threshold or seroprotective immune responses. Geometric mean antibody levels for all antigens were similar except for anti-PRP levels, which were 19.0 microg/mL in recipients of the licensed vaccine, 40.8 microg/mL in PRP-T/HBV10 recipients and 9.4 microg/mL in PRP-OMPC/HBV15 recipients. We conclude that the hexavalent formulations appear generally well tolerated and immunogenic as a booster dose in these toddlers.

译文

联合疫苗减少了注射次数,提高了父母的满意度和疫苗接种计划的依从性。在一项1期,随机,部分盲,单剂量加强研究中,我们评估了两种含白喉,破伤风,无细胞百日咳 (5组分),灭活脊髓灰质炎病毒,乙型流感嗜血杆菌结合物和乙型肝炎表面抗原 (DTaP-IPV-Hib-HBV) 在60名15至18个月大的健康幼儿中使用了三剂经许可的五价白喉,破伤风,无细胞百日咳 (5-组分),灭活脊髓灰质炎病毒,流感嗜血杆菌b偶联物 (DTaP-IPV // prp-t) 疫苗。DTaP-IPV // prp-t疫苗被用作30名受试者的对照。包含相同DTaP-IPV成分的研究性制剂仅在Hib (含量和结合物) 和HBV (含量) 方面有所不同 (prp-t/HBV10 = 12杯Hib破伤风类毒素结合物与10 microg HBsAg; prp-ompc/HBV15 = 6 microg Hib脑膜炎奈瑟氏菌外膜蛋白复合物与15 microg HBsAg)。46.7%,46.7% 和20.0% 的许可疫苗接受者,prp-t/HBV10接受者的43.3%,43.3% 和26.7% 以及prp-ompc/HBV15接受者的70.0%,46.7% 和46.7% 报告了注射部位疼痛,红肿。分别。经许可的疫苗接受者的0% 和16.7%,prp-t/HBV10接受者的10.3% 和23.3% 以及prp-ompc/HBV15接受者的30.0% 和16.7% 分别报告了发烧> 或 = 37.8摄氏度和烦躁不安。两组之间在达到预定义,阈值或血清保护性免疫反应的参与者比例方面没有明显差异。除抗-PRP水平外,所有抗原的几何平均抗体水平相似,抗-PRP水平在许可疫苗的接受者中是19.0微克/毫升,在prp-t/HBV10接受者中是40.8微克/毫升,在prp-ompc/HBV15接受者中是9.4微克/毫升。我们得出的结论是,在这些幼儿中,六价制剂通常表现出良好的耐受性和免疫原性,作为加强剂量。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录